Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods

Proteomics - Clinical Applications

Volumn 5, Issue 7-8, 2011, Pages 422-431

  Johnston, Olwyn ^a,b,c   Cassidy, Hilary ^a   O'Connell, Séin ^a   O'Riordan, Aisling ^a   Gallagher, William ^a   Maguire, Patricia B ^a   Wynne, Kieran ^a   Cagney, Gerard ^a   Ryan, Michael P ^a   Conlon, Peter J ^b   Mcmorrow, Tara ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

2 Microglobulin; Biomarkers; Chronic allograft nephropathy; Renal transplantation; SELDI TOF MS

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

ADULT; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SOFTWARE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960869429     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000160     Document Type: Article

References (45)

1. Solez, K., Axelsen, R. A., Benediktsson, H., Burdick, J. F. et al., International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993, 44, 411-422.
2. Bergmann, L., Roper, L., Bow, L. M., Hull, D. et al., Late graft loss in cadaveric renal transplantation. Transplant. Proc. 1992, 24, 2718-2719.
3. Sijpkens, Y. W., Doxiadis, I. I., Mallat, M. J., de Fijter, J. W. et al., Early versus late acute rejection episodes in renal transplantation. Transplantation 2003, 75, 204-208.
4. Cosio, F. G., Pelletier, R. P., Falkenhain, M. E., Henry, M. L. et al., Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997, 63, 1611-1615.
5. Hariharan, S., McBride, M. A., Cherikh, W. S., Tolleris, C. B. et al., Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002, 62, 311-318.
6. Nankivell, B. J., Borrows, R. J., Fung, C. L., O'Connell, P. J. et al., Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004, 78, 242-249.
7. Lo, A., Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors. Prog. Transplant. 2004, 14, 157-164.
8. Meier-Kriesche, H. U., Schold, J. D., Srinivas, T. R., Kaplan, B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 2004, 4, 378-383.
9. Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., Cosimi, A. B., Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 2002, 346, 580-590.
10. Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M. et al., The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999, 55, 713-723.
11. Afzali, B., Taylor, A. L., Goldsmith, D. J., What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. Kidney Int. 2005, 68, 2429-2443.
12. Sarwal, M., Chua, M. S., Kambham, N., Hsieh, S. C. et al., Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 2003, 349, 125-138.
13. Rapkiewicz, A. V., Espina, V., Petricoin III E. F., Liotta, L. A., Biomarkers of ovarian tumours. Eur. J. Cancer 2004, 40, 2604-2612.
14. Conrads, T. P., Fusaro, V. A., Ross, S., Johann, D. et al., High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 2004, 11, 163-178.
15. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
16. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., Chan, D. W., Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002, 48, 1296-1304.
17. Ornstein, D. K., Rayford, W., Fusaro, V. A., Conrads, T. P. et al., Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0ng/ml. J. Urol. 2004, 172, 1302-1305.
18. Petricoin, E. F., Ornstein, D. K., Paweletz, C. P., Ardekani, A. et al., Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 2002, 94, 1576-1578.
19. O'Riordan, E., Orlova, T. N., Mei, J. J., Butt, K. et al., Bioinformatic analysis of the urine proteome of acute allograft rejection. J. Am. Soc. Nephrol. 2004, 15, 3240-3248.
20. Schaub, S., Rush, D., Wilkins, J., Gibson, I. W. et al., Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2004, 15, 219-227.
21. Clarke, W., Silverman, B. C., Zhang, Z., Chan, D. W. et al., Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. 2003, 237, 660-664.
22. Li, J., Orlandi, R., White, C. N., Rosenzweig, J. et al., Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 2005, 51, 2229-2235.
23. Ruetschi, U., Zetterberg, H., Podust, V. N., Gottfries, J. et al., Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 2005, 196, 273-281.
24. Traum, A. Z., Schachter, A. D., Transplantation proteomics. Pediatr. Transplant. 2005, 9, 700-711.
25. Cutillas, P., Burlingame, A., Unwin, R., Proteomic strategies and their application in studies of renal function. News Physiol. Sci. 2004, 19, 114-119.
26. Wilczek, H. E., Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation 1990, 50, 790-797.
27. Schaub, S., Wilkins, J., Weiler, T., Sangster, K. et al., Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004, 65, 323-332.
28. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K. et al., Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
29. O'Riordan, A., Johnston, O., McMorrow, T., Wynne, K. et al., Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. Proteomics Clin. Appl. 2008, 2, 1338-1348.
30. Nesvizhskii, A. I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75, 4646-4658.
31. Yates III J. R., Eng, J. K., McCormack, A. L., Schieltz, D., Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal. Chem. 1995, 67, 1426-1436.
32. Coppinger, J. A., Cagney, G., Toomey, S., Kislinger, T. et al., Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103, 2096-2104.
33. Schaub, S., Wilkins, J. A., Antonovici, M., Krokhin, O. et al., Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 2005, 5, 729-738.
34. Camara, N. O., Silva, M. S., Nishida, S., Pereira, A. B., Pacheco-Silva, A., Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renal-graft survival. Transplantation 2004, 78, 269-275.
35. Rogier, E., Durrbach, A., Abecassis, L., Ferlicot, S. et al., A novel biological assay to detect the active form of TGF-beta in urine to monitor renal allograft rejection. Kidney Int. 2005, 68, 1875-1883.
36. Teppo, A. M., Honkanen, E., Finne, P., Tornroth, T., Gronhagen-Riska, C., Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome. Transplantation 2004, 78, 719-724.
37. Plesner, T., Bjerrum, O. J., Distribution of 'free' and HLA-associated human beta 2-microglobulin in some plasma membranes and biological fluids. Scand. J. Immunol. 1980, 11, 341-351.
38. Schardijn, G. H., Statius van Eps, L. W., Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987, 32, 635-641.
39. Woo, K. T., Lee, E. J., Lau, Y. K., Lim, C. H., Beta-2-microglobulin in the assessment of renal function of the transplanted kidney. Nephron 1985, 39, 223-227.
40. Sumboonnanonda, A., Malasit, P., Tanphaichitr, V. S., Ong-ajyooth, S. et al., Renal tubular dysfunction in alpha-thalassemia. Pediatr. Nephrol. 2003, 18, 257-260.
41. Bernard, A., Renal dysfunction induced by cadmium: biomarkers of critical effects. Biometals 2004, 17, 519-523.
42. Pertovaara, M., Korpela, M., Pasternack, A., Factors predictive of renal involvement in patients with primary Sjogren's syndrome. Clin. Nephrol. 2001, 56, 10-18.
43. Ryu, O. H., Atkinson, J. C., Hoehn, G. T., Illei, G. G., Hart, T. C., Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology 2006, 45, 1077-1086.
44. Greipp, P. R., San Miguel, J., Durie, B. G., Crowley, J. J. et al., International staging system for multiple myeloma. J. Clin. Oncol. 2005, 23, 3412-3420.
45. Scheffer, G. L., de Jong, M. C., Monks, A., Flens, M. J. et al., Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells. Br. J. Cancer 2002, 86, 1943-1950.